CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)
Clinical trial NCT04060407 · WITHDRAWN
Trial details
- NCT number
- NCT04060407
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Status
- WITHDRAWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-15
- Primary completion
- 2022-12-30
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.